PSMA-targeted theranostic nanocarrier for prostate cancer Journal Article
| Authors: | Flores, O.; Santra, S.; Kaittanis, C.; Bassiouni, R.; Khaled, A. S.; Khaled, A. R.; Grimm, J.; Perez, J. M. |
| Article Title: | PSMA-targeted theranostic nanocarrier for prostate cancer |
| Abstract: | Herein, we report the use of a theranostic nanocarrier (Folate-HBPE(CT20p)) to deliver a therapeutic peptide to prostate cancer tumors that express PSMA (folate hydrolase 1). The therapeutic peptide (CT20p) targets and inhibits the chaperonin-containing TCP-1 (CCT) protein-folding complex, is selectively cytotoxic to cancer cells, and is non-toxic to normal tissue. With the delivery of CT20p to prostate cancer cells via PSMA, a dual level of cancer specificity is achieved: (1) selective targeting to PSMA-expressing prostate tumors, and (2) specific cytotoxicity to cancer cells with minimal toxicity to normal cells. The PSMA-targeting theranostic nanocarrier can image PSMA-expressing cells and tumors when a near infrared dye is used as cargo. Meanwhile, it can be used to treat PSMA-expressing tumors when a therapeutic, such as the CT20p peptide, is encapsulated within the nanocarrier. Even when these PSMA-targeting nanocarriers are taken up by macrophages, minimal cell death is observed in these cells, in contrast with doxorubicin-based therapeutics that result in significant macrophage death. Incubation of PSMA-expressing prostate cancer cells with the Folate-HBPE(CT20p) nanocarriers induces considerable changes in cell morphology, reduction in the levels of integrin ß1, and lower cell adhesion, eventually resulting in cell death. These results are relevant as integrin ß1 plays a key role in prostate cancer invasion and metastatic potential. In addition, the use of the developed PSMA-targeting nanocarrier facilitates the selective in vivo delivery of CT20p to PSMA-positive tumor, inducing significant reduction in tumor size. © Ivyspring International Publisher. |
| Keywords: | peptide; prostate cancer; psma; polymeric nanoparticles |
| Journal Title: | Theranostics |
| Volume: | 7 |
| Issue: | 9 |
| ISSN: | 1838-7640 |
| Publisher: | Ivyspring International Publisher |
| Date Published: | 2017-01-01 |
| Start Page: | 2477 |
| End Page: | 2494 |
| Language: | English |
| DOI: | 10.7150/thno.18879 |
| PROVIDER: | scopus |
| PMCID: | PMC5525751 |
| PUBMED: | 28744329 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 August 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work